The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by an incompletely reversible limitation in airflow. A physiological variable--the forced expiratory volume in one second (FEV1)--is often used to grade the severity of COPD. However, patients with COPD have systemic manifestations that are not reflected by the FEV1. We hypothesized that a multidimensional grading system that assessed the respiratory and systemic expressions of COPD would better categorize and predict outcome in these patients. METHODS: We first evaluated 207 patients and found that four factors predicted the risk of death in this cohort: the body-mass index (B), the degree of airflow obstruction (O) and dyspnea (D), and exercise capacity (E), measured by the six-minute-walk test. We used these variables to construct the BODE index, a multidimensional 10-point scale in which higher scores indicate a higher risk of death. We then prospectively validated the index in a cohort of 625 patients, with death from any cause and from respiratory causes as the outcome variables. RESULTS: There were 25 deaths among the first 207 patients and 162 deaths (26 percent) in the validation cohort. Sixty-one percent of the deaths in the validation cohort were due to respiratory insufficiency, 14 percent to myocardial infarction, 12 percent to lung cancer, and 13 percent to other causes. Patients with higher BODE scores were at higher risk for death; the hazard ratio for death from any cause per one-point increase in the BODE score was 1.34 (95 percent confidence interval, 1.26 to 1.42; P<0.001), and the hazard ratio for death from respiratory causes was 1.62 (95 percent confidence interval, 1.48 to 1.77; P<0.001). The C statistic for the ability of the BODE index to predict the risk of death was larger than that for the FEV1 (0.74 vs. 0.65). CONCLUSIONS: The BODE index, a simple multidimensional grading system, is better than the FEV1 at predicting the risk of death from any cause and from respiratory causes among patients with COPD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [166]
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [42]
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [42]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043
Lung Function Testing: Selection of Reference Values and Interpretative Strategies
(1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.5.1202 · Cited by 2,510
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
Evaluation of Clinical Methods for Rating Dyspnea
Mahler, D. A., & Wells, C. K. (1988) · Chest · doi:10.1378/chest.93.3.580 · Cited by 1,822
Research works printed but not linked: 1
- Burrows B, 1991, Eur Respir Rev, 1, 340
Cited by
Items 701–800 of 1,007
Rubio, M. C., Casamor, R., & Miravitlles, M. (2017) · International Journal of COPD · doi:10.2147/copd.s137872 · Cited by 59
COPD stands for complex obstructive pulmonary disease
Houben‐Wilke, S., Augustin, I. M. L., Vercoulen, J. H., van Ranst, D., de Vaate, E. B., Wempe, J. B., Spruit, M. A., Wouters, E. F. �., & Franssen, F. M. E. (2018) · European Respiratory Review · doi:10.1183/16000617.0027-2018 · Cited by 60
Makris, D. A., Paraskakis, E., Korakas, P., Karagiannakis, E., Sourvinos, G., Siafakas, N. M., & Tzanakis, N. (2007) · Respiration · doi:10.1159/000106377 · Cited by 59
“A plausible explanation for this dissociation is that sputum neutrophilia reflects inflammation in central airways but not in small airways and alveoli [”
BackgroundAksu, F., Çapan, N., Aksu, K., Ofluoğlu, R., Canbakan, S., Yavuz, B., & Akın, K. O. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.06.27 · Cited by 72
Laurin, C., Labrecque, M., Dupuis, G., Bacon, S. L., Cartier, A., & Lavoie, K. L. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181a82849 · Cited by 57
“As previously published (14), we used a composite measure of COPD severity (24) which included body mass index (BMI), FEV1, and MRC score (scored on a 7-point scale, with a higher score indicating more severe disease).”
MethodAmorós, M. M., Mas-Tous, C., Renom-Sotorra, F., Rubí-Ponseti, M., Centeno-Flores, M., & Gorriz-Dolz, M. (2009) · Chronic Respiratory Disease · doi:10.1177/1479972308101551 · Cited by 67
How do COPD comorbidities affect ICU outcomes?
Akkütük, E., Karakurt, Z., Saltürk, C., Burunsuzoğlu, B., Kargın, F., Horzum, G., Moçin, Ö. Y., Güngör, G., Adıgüzel, N., Yılmaz, A., et al. (2014) · International Journal of COPD · doi:10.2147/copd.s70257 · Cited by 62
“mortality of COPD patients whose BMI score is ,40 kg/m(2).(34) A recent study of 94 intubated patients investigated the effect of BMI on weaning trials.”
BackgroundPhysical Activity In Daily Life In Brazilian COPD Patients During and After Exacerbation
Borges, R. C., & Carvalho, C. R. F. (2012) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2012.705364 · Cited by 69
Eskander, A. E., Waddell, T. K., Faughnan, M. E., Chowdhury, N., & Singer, L. G. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.06.006 · Cited by 58
Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat
Thomas, N., Naik, D., Joshi, A., & Paul, T. V. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.139212 · Cited by 64
“[25,26] ] In patients with COPD, obesity has an unusual impact that is commonly, referred as “Reverse Epidemiology of Obesity”.”
A ferret model of COPD-related chronic bronchitis
Raju, S. V., Kim, H., Byzek, S. A., Tang, L. P., Trombley, J. E., Jackson, P. L., Rasmussen, L. W., Wells, J. M., Libby, E. F., Dohm, E. D., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87536 · Cited by 65
de Blasio, F., Blasio, F. D., Berlingieri, G. M., Bianco, A., Greca, M. L., Franssen, F. M. E., & Scalfi, L. (2016) · International Journal of COPD · doi:10.2147/copd.s110364 · Cited by 62
“42 A composite prognostic index, the BODE index, 43 was used as surrogate of global disease severity.”
Chronic Obstructive Pulmonary Disease: Lobar Analysis with Hyperpolarized 129Xe MR Imaging
Matin, T., Rahman, N. M., Nickol, A. H., Chen, M., Xu, X., Stewart, N. J., Doel, T., Grau, V., Wild, J. M., & Gleeson, F. V. (2016) · Radiology · doi:10.1148/radiol.2016152299 · Cited by 58
“perpolarized (3) He and (129) Xe MRI: dif-”
BackgroundMethodInfluentialElevated GDF-15 contributes to pulmonary inflammation upon cigarette smoke exposure
Verhamme, F. M., Seys, L., Smet, E. G. D., Provoost, S., Janssens, W., Elewaut, D. S., Joos, G., Brusselle, G., & Bracke, K. R. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.3 · Cited by 58
“In patients with COPD, weight loss is an unfavorable prognostic marker as evidenced in the BODE (Body-mass index, Obstruction, Dyspnea, and Exercise capacity) index.(16) Recently, increased serum levels of GDF-15 have been shown in patients with COPD under stable conditions and during acute exacerbations.”
BackgroundSandberg, J., Ekström, M. P., Börjesson, M., Bergström, G. M. L., Rosengren, A., Angerås, O., & Torén, K. (2020) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000643 · Cited by 59
Prueba de caminata en seis minutos en sujetos chilenos sanos de 20 a 80 años
Rodrigo Osses, A., YÁÑEZ, J., V, Paulina Barría, P., Sylvia Palacios, M., Jorge Dreyse, D., Orlando Díaz, P., & Carmen Lisboa, B. (2010) · Revista médica de Chile · doi:10.4067/s0034-98872010000900006 · Cited by 86
Pathogenesis of Bacterial Exacerbations of COPD
Veeramachaneni, S. B., & Sethi, S. (2006) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550600651347 · Cited by 64
Proposal for a multidimensional staging system for chronic obstructive pulmonary disease
Celli, B. R., Calverley, P. M. A., Rennard, S. I., Wouters, E. F. �., Agustí, A. G. N., Anthonisen, N. R., MacNee, W., Jones, P., Pride, N. B., Rodriguez‐Roisin, R., et al. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.03.019 · Cited by 70
“A recent publication documents the value of a multidimensional index that included BMI (B), degree of airflow obstruction (O), dyspnea (D) and exercise performance (E) or BODE index, to predict mortality.(17) This paper describes a different approach aimed at developing a staging system which should be both relatively…”
BackgroundMethodInfluentialSelf-citationMortality of patients with COPD
Halpin, D. M. G. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2375416 · Cited by 64
“These include the BODE (body mass index, FEV1, dyspnea, and exercise capacity) and ADO (age, dyspnea, and FEV 1 ) indices [73,74].”
Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI
Huertas, A., Testa, U., Riccioni, R., Petrucci, E., Riti, V., Savi, D., Serra, P., Bonsignore, M. R., & Palange, P. (2009) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2009.10.003 · Cited by 60
Rehman, S., Martinez‐Rumayor, A., Mueller, T., & Januzzi, J. L. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.03.002 · Cited by 63
Nishiyama, K., Morimoto, T., Furukawa, Y., Nakagawa, Y., Ehara, N., Taniguchi, R., Ozasa, N., Saito, N., Hoshino, K., Touma, M., et al. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.02.010 · Cited by 57
“Previous studies have shown that patients with COPD have a significantly higher risk of long-term all-cause mortality after PCI and CABG [5–14].”
BackgroundPrevalence and assessment of breathlessness in the clinical setting
Johnson, M. J., Currow, D. C., & Booth, S. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2014.879530 · Cited by 66
“Prevalence estimates for non-malignant cardiorespiratory diseases range from 60 to 88% (heart failure) and 90 to 95% (COPD) [20].”
BackgroundInfluentialObesity as a susceptibility factor to indoor particulate matter health effects in COPD
McCormack, M. C., Belli, A. J., Kaji, D. A., Matsui, E. C., Brigham, E. P., Peng, R. D., Sellers, C. M., Williams, D. L., Diette, G. B., Breysse, P. N., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00081414 · Cited by 58
Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective
Dai, J., Yang, P., Cox, A., & Jiang, G. (2017) · Oncotarget · doi:10.18632/oncotarget.14505 · Cited by 58
“However, screening patients with more severe COPD may reduce cost-effectiveness because the benefits could be surpassed by other competing causes of death inherent to COPD [61].”
BackgroundDiago, C. A. A., García‐Unzueta, M. T., Lavín, B. A., Guerra-Ruiz, A. R., Calvo, J. A., Ramos, L., & Muñoz, P. (2018) · Respiration · doi:10.1159/000494296 · Cited by 61
Chronic Obstructive Pulmonary Disease Outcome Measurements: What's Important? What's Useful?
Gross, N. J. (2005) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200504-036sr · Cited by 62
Development of a decision tree to assess the severity and prognosis of stable COPD
Esteban, C., Aróstegui, I., Moraza, J., Aburto, M., Quintana, J. M., Pérez‐Izquierdo, J., Aizpiri, S., & Capelastegui, A. (2011) · European Respiratory Journal · doi:10.1183/09031936.00189010 · Cited by 66
Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Suissa, S., McGhan, R. M., Niewoehner, D. E., & Make, B. J. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-024fm · Cited by 57
Chen, H., Song, Z., Qian, M., Bai, C., & Wang, X. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01416.x · Cited by 56
“Previous assessments such as BODE index [33] could be used to monitor and provide good predictive information in a clinical practice.”
MethodGender Differences in Plasma Biomarker Levels in a Cohort of COPD Patients: A Pilot Study
de-Torres, J. P., Casanova, C., Pinto-Plata, V., Varo, N., Restituto, P., Córdoba-Lanús, E., Baz‐Dávila, R., Aguirre‐Jaime, A., & Celli, B. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016021 · Cited by 60
Self-citationDevelopment, dimensions, reliability and validity of the novel Manchester COPD fatigue scale
Al-shair, K., Kolsum, U., Berry, P., Smith, J. A., Caress, A., Singh, D., & Vestbo, J. (2009) · Thorax · doi:10.1136/thx.2009.118109 · Cited by 55
Biomechanical CT metrics are associated with patient outcomes in COPD
Bodduluri, S., Bhatt, S. P., Hoffman, E. A., Newell, J. D., Martínez, C. H., Dransfield, M. T., Han, M. K., & Reinhardt, J. M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209544 · Cited by 64
Body composition and sarcopenia in patients with chronic obstructive pulmonary disease
Costa, T. M. D. R. L., Costa, F. M., Jonasson, T. H., Moreira, C. A., Boguszewski, C. L., & Borba, V. Z. C. (2018) · Endocrine · doi:10.1007/s12020-018-1533-4 · Cited by 68
Gáldiz, J. B., Gómez, A., Rodriguez, D. A., Güell, R., Cebollero, P., Hueto, J., Cejudo, P., Ruiz, F. Ó., Sayago, I., Chic, S., et al. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2020.03.034 · Cited by 61
Dávalos‐Yerovi, V., Marco, E., Sánchez‐Rodríguez, D., Durán, X., Meza-Valderrama, D., Rodriguez, D. A., Muñoz, E., Tejero-Sánchez, M., Muns, M. D., Guillén-Solà, A., et al. (2021) · Nutrients · doi:10.3390/nu13020369 · Cited by 62
“On this 10-point scale, higher scores indicate a higher risk of death [24].”
BackgroundDu, Y., Yang, C.-J., Li, B., Wu, X., Lv, Y., Jin, H., Cao, Y., Sun, J., Luo, Q., Gong, W., et al. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.020 · Cited by 61
“The test was repeated twice with an interval of at least 30 min (Celli et al., 2004).”
The Epidemiology, Etiology, Clinical Features, and Natural History of Emphysema
Kemp, S. V., Polkey, M. I., & Shah, P. L. (2009) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2009.03.003 · Cited by 58
“The most established of these is the BODE score, incorporating BMI, the degree of airflow Obstruction, Dyspnoea, and Exercise capacity.(57) The total score obtained correlates better than the FEV1 with all-cause and respiratory mortality, and analysis of the NETT data shows that the change in a modified BODE score is…”
MethodDefining Phenotypes in COPD: An Aid to Personalized Healthcare
Segreti, A., Stirpe, E., Rogliani, P., & Cazzola, M. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0100-9 · Cited by 55
“Celli and colleagues hypothesized that FEV1 is not enough to estimate severity of COPD, and that a multidimensional approach would better grade the disease and predict the outcome with respect to the use of the FEV1 alone [3].”
BackgroundChest CT ‐assessed comorbidities and all‐cause mortality risk in COPD patients in the BODE cohort
Ezponda, A., Casanova, C., Divo, M. J., Marín‐Oto, M., Cabrera, C., Marín, J. M., Bastarrika, G., Pinto-Plata, V., Martín-Palmero, Á., Polverino, F., et al. (2022) · Respirology · doi:10.1111/resp.14223 · Cited by 62
Self-citationPinto-Plata, V., Celli-Cruz, R. A., Vassaux, C., Torre-Bouscoulet, L. I., Mendes, A., Rassulo, J., & Celli, B. R. (2007) · CHEST Journal · doi:10.1378/chest.07-0593 · Cited by 58
Self-citationUse of a Soluble Epoxide Hydrolase Inhibitor in Smoke-Induced Chronic Obstructive Pulmonary Disease
Wang, L., Yang, J., Guo, L., Uyeminami, D. L., Dong, H., Hammock, B. D., & Pinkerton, K. E. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0359oc · Cited by 55
“Chronic obstructive pulmonary disease (COPD) is amajor cause of morbidity and mortality worldwide, and is expected to become the third leading cause of death by 2020 (1).”
Mass of intercostal muscles associates with risk of multiple exacerbations in COPD
Güerri‐Fernández, R., Gayete, Á., Balcells, E., Ramírez-Sarmiento, A., Vollmer, I., García‐Aymerich, J., Gea, J., & Orozco‐Levi, M. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.10.015 · Cited by 56
“A new severity classification was proposed: the BODE index (BMI, airflow obstruction, dyspnea and exercise capacity).(33) Nevertheless, it is generally suggested that the true factor underlying the negative effects attributed to malnutrition is muscle depletion, not total body weight loss.”
Sensing, physiological effects and molecular response to elevated CO 2 levels in eukaryotes
Sharabi, K., Lecuona, E., Helenius, I. T., Beitel, G. J., Sznajder, J. I., & Gruenbaum, Y. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00952.x · Cited by 55
Lenferink, A., Frith, P. A., van der Valk, P., Buckman, J., Sladek, R., Cafarella, P., van der Palen, J. A. M., & Effing, T. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.06.003 · Cited by 56
“A six minute walking test (in duplicate) [45] will be performed at baseline tomeasure exercise capacity and provides one component of the index of COPD severity, the BODE score [40].”
MethodSilverman, E. K., Vestbo, J., Agustí, A. G. N., Anderson, W. H., Bakke, P. S., Barnes, K. C., Barr, R. G., Bleecker, E. R., Boezen, H. M., Burkart, K. M., et al. (2011) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2011.558864 · Cited by 65
“These characteristics can practically be integrated into multidimensional tools such as the BODE index capable of providing a more comprehensive evaluation of COPD subjects (34).”
MethodSelf-citationRole of the Timed Up and Go Test in Patients With Chronic Obstructive Pulmonary Disease
Alhaddad, M., John, M., Hussain, S., & Bolton, C. E. (2015) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000143 · Cited by 59
Weight Gain in Cachectic COPD Patients Receiving Noninvasive Positive-Pressure Ventilation
Budweiser, S., Heinemann, F., Meyer, K., Wild, P. J., & Pfeifer, M. (2006) · Respiratory Care · doi:10.4187/respcare.06510126 · Cited by 72
Predictors of Mortality in Patients with Stable COPD
Esteban, C., Quintana, J. M., Aburto, M., Moraza, J., Egurrola, M., España, P. P., Pérez‐Izquierdo, J., & Capelastegui, A. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0783-x · Cited by 55
“1 44 (7) 43 (10) 1 (1) 2 306 (50) 243 (55) 63 (38) 3 233 (38) 147 (33) 86 (52) 4–5 28 (4) 12 (3) 16 (10) Mean VAS dyspnea, (SD) 49.”
Safety of indacaterol in the treatment of patients with COPD
Donohue, J. F., Singh, D., Kornmann, O., Lawrence, Lassen, & Krämer, B. (2011) · International Journal of COPD · doi:10.2147/copd.s23816 · Cited by 54
Ferrari, R., Caram, L., Faganello, M., Sanchez, F., Tanni, S., & Godoy, I. (2015) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s85954 · Cited by 52
“BODE scores were categorized as class 1 (0–2), class 2 (3–4), class 3 (5–6), and class 4 (7–10).(18)”
BackgroundMethodInfluentialDiagnosis and Management of Chronic Obstructive Pulmonary Disease: The Swiss Guidelines
Russi, E. W., Karrer, W. L., Brutsche, M. H., Eich, C., Fitting, J. W., Frey, M., Geiser, T., Kuhn, M. U., Nicod, L. P., Quadri, F., et al. (2013) · Respiration · doi:10.1159/000346025 · Cited by 62
Chronic Obstructive Pulmonary Disease with Lung Cancer and/or Cardiovascular Disease
Rodriguez‐Roisin, R., & Soriano, J. B. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200807-075th · Cited by 54
Tanash, H. A., Riise, G. C., Hansson, L., Nilsson, P. M., & Piitulainen, E. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.07.003 · Cited by 55
Almagro, P., Martínez‐Camblor, P., Soriano, J. B., Marín, J. M., Alfageme, I., Casanova, C., Esteban, C., Soler‐Cataluña, J. J., de-Torres, J. P., Celli, B. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089866 · Cited by 62
“The two common variables included in all multidimensional prognostic indices in COPD are respiratory function – measured with postbronchodilator FEV1 (%)– and dyspnea.[4,6,7,9] However the cutoffs used are different among them.”
BackgroundSelf-citationRoutine Laboratory Tests can Predict In-hospital Mortality in Acute Exacerbations of COPD
Asiimwe, A., Brims, F., Andrews, N. P., Prytherch, D. R., Higgins, B., Kilburn, S. A., & Chauhan, A. (2011) · Lung · doi:10.1007/s00408-011-9298-z · Cited by 57
de-Torres, J. P., Casanova, C., Marín, J. M., Zagaceta, J., Alcaide, A. B., Seijo, L. M., Campo, A., Carrizo, S. J., Montes, U., Córdoba-Lanús, E., et al. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.01.013 · Cited by 54
Self-citationGlobal assessment of the COPD patient: Time to look beyond FEV1?
Papaioannou, A. Ι., Loukides, S., Gourgoulianis, K. I., & Κostikas, Κ. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.01.001 · Cited by 60
Yu, L., Mazancourt, M. D., Hess, A., Ashadi, F. R., Klein, I. F., Mal, H., Courbage, M., & Mangin, L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23205 · Cited by 58
“, 2001] and the multidimensional BODE index based on BMI, FEV1, dyspnea severity (MRC), and the 6-min walking distance [Celli et al., 2004].”
MethodPerrot, L., Greil, A., Boirie, Y., Farigon, N., Mulliez, A., Costes, F., & Caillaud, D. M. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0623-6 · Cited by 62
Mahler, D., Waterman, L. A., Ward, J., McCusker, C., ZuWallack, R., & Baird, J. (2007) · Chest · doi:10.1378/chest.07-0703 · Cited by 54
Longitudinal assessment in COPD patients: multidimensional variability and outcomes
Casanova, C., Aguirre‐Jaime, A., de-Torres, J. P., Pinto-Plata, V., Baz, R., Marín, J. M., Divo, M. J., Córdoba-Lanús, E., Basaldúa, S., Côté, C., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00096913 · Cited by 56
Self-citationPlasma mi RNAs might be promising biomarkers of chronic obstructive pulmonary disease
Wang, M., Huang, Y., Liang, Z., Liu, D., Lu, Y., Dai, Y., Guanglin, F., & Wang, C. (2014) · The Clinical Respiratory Journal · doi:10.1111/crj.12194 · Cited by 53
Ringbæk, T., Martinez, G., Brøndum, E., Thøgersen, J., Morgan, M. D., & Lange, P. (2010) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e3181e1736b · Cited by 53
“Covariates in the univariate analysis model were gender, age (y), smoking status (yes/no), pack-years, body mass index (kg/m2), oxygen saturation at rest, Medical Research Council dyspnea score (1-5), maintenance treatment oral corticosteroids (yes/no), LTOT, and FEV1 percentage of predicted value.”
MethodTousignant, M., Marquis, N., Pagé, C., Imukuze, N., Métivier, A., St-Onge, V., & Tremblay, A. (2012) · International Journal of Telerehabilitation · doi:10.5195/ijt.2012.6083 · Cited by 55
“This test is frequently used to evaluate the functional capacity of patients with COPD (Celli et al., 2004; Rasekaba et al., 2009).”
MethodMicrofibrillar-associated protein 4: A potential biomarker of chronic obstructive pulmonary disease
Johansson, S. L., Roberts, N. B., Schlosser, A. G., Andersen, C. B., Carlsen, J., Wulf-Johansson, H., Sækmose, S. G., Titlestad, I. L., Tornøe, I., Miller, B. E., et al. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.06.003 · Cited by 53
Gender differences in survival following hospitalisation for COPD
Gonzalez, A. V., Suissa, S., & Ernst, P. (2010) · Thorax · doi:10.1136/thx.2010.141978 · Cited by 54
Stanford Seven-Day Physical Activity Recall questionnaire in COPD
Garfield, B. E., Canavan, J. L., Smith, C. J., Ingram, K. A., Fowler, R. P., Clark, A. L., Polkey, M. I., & Man, W. D.-C. (2012) · European Respiratory Journal · doi:10.1183/09031936.00113611 · Cited by 49
Kim, T. H., Ki, C., Kim, H. S., Kim, K., Choe, J., Kim, J., Kim, J. S., Oh, Y. L., Hahn, S. Y., Shin, J. H., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3434 · Cited by 55
“0 (with higher values being better) (23).”
Cleutjens, F. A. H. M., Spruit, M. A., Ponds, R., Vanfleteren, L. E. G. W., Franssen, F. M. E., Gijsen, C., Dijkstra, J. B., Wouters, E. F. �., & Janssen, D. J. A. (2017) · Chronic Respiratory Disease · doi:10.1177/1479972317709651 · Cited by 53
Effects of exercise training in water and on land in patients with COPD: a randomised clinical trial
Felcar, J. M., Probst, V. S., de Carvalho, D. R., Merli, M. F., Mesquita, R., Vidotto, L. S., Ribeiro, L. R. G., & Pitta, F. D. O. (2018) · Physiotherapy · doi:10.1016/j.physio.2017.10.009 · Cited by 53
Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
Brigham, E. P., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Cowans, N. J., Crim, C. C., Diserens, J. E., Martínez, F. J., McCormack, M. C., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00902-2020 · Cited by 58
“This cut-off point may reduce comparability with other disease states, and falls between the BMI of 21 kg·m − 2 in the BODE index [39] and 18.5 kg·m − 2 in WHO guidelines [17] to define at-risk/underweight populations.”
InfluentialSelf-citationLim, S., Kwon, S., Yoon, J. W., Kim, S. Y., Choi, S. H., Park, Y. J., Yoon, H. I., Chang, Y. S., Lee, J. H., Lee, C., et al. (2011) · Obesity · doi:10.1038/oby.2010.167 · Cited by 52
“Prior studies of body composition were based largely on indirect estimates based on anthropometric data such as BMI or waist circumference (15,41).”
BackgroundOng, K.-C., Lu, S.-J., & Soh, C. (2006) · International Journal of COPD · doi:10.2147/copd.2006.1.1.91 · Cited by 53
“The multidimensional staging system of the BODE index has already been shown to be a superior predictor of the risk of death in COPD patients compared with the FEV 1 -based staging system by the ATS (Celli et al 2004).”
BackgroundMethodResultInfluentialLerario, M. C., Sachs, A., Lazaretti‐Castro, M., Saraiva, L. G. M., & Jardim, J. R. (2006) · British Journal Of Nutrition · doi:10.1079/bjn20061798 · Cited by 53
“Recently Celli et al. (2004) developed a four-variable (including BMI) multi-systemic index (body-mass-index, airflow obstruction, dyspnoea, and exercise capacity index) to predict mortality in COPD patients that once again proves the importance of body composition for COPD patients. In contrast, the occurrence of nor…”
InfluentialCommunication about Palliative Care for Patients with Chronic Obstructive Pulmonary Disease
Curtis, J. R., Engelberg, R. A., Wenrich, M. D., & Au, D. H. (2005) · Journal of Palliative Care · doi:10.1177/082585970502100308 · Cited by 53
“COPO may l~prove prognostic accuracy for groups of patients, but do not predict survival for individual patients with comparable accuracy, as can be done for many patients with lung cancer (17).”
BackgroundLung Volume Reduction Therapies for Advanced Emphysema
Berger, R. L., DeCamp, M. M., Criner, G. J., & Celli, B. R. (2010) · CHEST Journal · doi:10.1378/chest.09-1822 · Cited by 52
Self-citationLei, T., Lu, T., Yu, H., Su, X., Zhang, C., Zhu, L., Yang, K., & Liu, J. (2022) · International Journal of COPD · doi:10.2147/copd.s368645 · Cited by 59
“Catalase and glutathione peroxidase neutralize H2O2 into water and oxygen.(28,29,42) Peh et al showed that inhibition of the activities of these three key antioxidant enzymes would increase oxidative stress, which contributed to the incidence of emphysema.”
BackgroundBiomarkers, the control panel and personalized COPD medicine
Agustí, A. G. N., Gea, J., & Faner, R. (2015) · Respirology · doi:10.1111/resp.12585 · Cited by 59
Nowak, C., Sievi, N. A., Clarenbach, C. F., Schwarz, E. I., Schlatzer, C., Brack, T., Brutsche, M. H., Frey, M., Irani, S., Leuppi, J. D., et al. (2014) · Pulmonary Medicine · doi:10.1155/2014/973858 · Cited by 52
Bettoncelli, G., Blasi, F., Brusasco, V., Centanni, S., Corrado, A., Benedetto, F. D., Michele, F. D., Maria, G. U. D., Donner, C. F., Falcone, F., et al. (2014) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-9-25 · Cited by 60
The changing face of a rare disease: lymphangioleiomyomatosis
Harari, S. A., Torre, O., Cassandro, R., & Moss, J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00412-2015 · Cited by 54
Blervaque, L., PREFAUT, C. G., Forthin, H., Maffre, F., Bourrelier, M., Héraud, N., Catteau, M., Pomiès, P., Jaffuel, D., Molinari, N., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01674-3 · Cited by 53
“The BODE index was calculated as previously described [18].”
MethodColeta, K. D., Silveira, L. V. D. A., Lima, D. F., Rampinelli, E. A., de Godoy, I., & Godoy, I. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2007.12.003 · Cited by 57
“variable for 1-year survival; however, in this study were included COPD patients with a wide range of disease severity.(28) Relationship between dyspnea perception and 5-year survival was evaluated in other studies.”
MethodKiller cells in chronic obstructive pulmonary disease
Fairclough, L. C., Urbanowicz, R. A., Corne, J. M., & Lamb, J. R. (2008) · Clinical Science · doi:10.1042/cs20070356 · Cited by 58
A cost-aware framework for the development of AI models for healthcare applications
Erion, G., Janizek, J. D., Hudelson, C. E., Utarnachitt, R. B., McCoy, A. M., Sayre, M. R., White, N. J., & Lee, S. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00872-8 · Cited by 73
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 65
ZuWallack, R. (2007) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550701480620 · Cited by 51
“The MRC score has demonstrated importance is an independent predictor of survival in COPD as a component of the multi-dimensional BODE (Body mass index, Obstruction (FEV1), Dyspnea (MRC), Exercise (6-minute walk distance) score (17).”
BackgroundActivity restriction in mild COPD: a challenging clinical problem
O'Donnell, D. E., & Gebke, K. B. (2014) · International Journal of COPD · doi:10.2147/copd.s62766 · Cited by 59
“7).(87) The CAT is a questionnaire used to measure the overall impact of COPD on a patient’s life.”
Tashkin, D. P. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.837159 · Cited by 57
“Weight loss in underweight patients is potentially concerning since a low BMI is a significant risk factor for death is COPD [43].”
BackgroundExercise Testing in Severe Emphysema: Association with Quality of Life and Lung Function
Brown, C. D., Benditt, J. O., Sciurba, F. C., Lee, S. M., Criner, G. J., Mosenifar, Z., Shade, D. M., Slivka, W. A., & Wise, R. A. (2008) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550801941265 · Cited by 59
“Currently it is widely used in clinical trials as a functional outcome as well as a predictor of mortality (2, 3).”
BackgroundPulmonary rehabilitation: a review of the recent literature.
Goldstein, R., Hill, K., Brooks, D., & Dolmage, T. (2012) · Chest · doi:10.1378/chest.12-0188 · Cited by 49
Cohort profile: Greifswald approach to individualized medicine (GANI_MED)
Grabe, H. J., Assel, H., Bahls, T., Dörr, M., Endlich, K., Endlich, N., Erdmann, P., Ewert, R., Felix, S. B., Fiene, B., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-144 · Cited by 53
“Hence the generation of established prognostic indices (Bode-Index [45], ADO-Index [46]) and recent COPD graduations [47] is possible.”
Importance of Biomarkers for Long-Term Mortality Prediction in Acutely Dyspneic Patients
Januzzi, J. L., Rehman, S., Mueller, T., van Kimmenade, R. R. J., & Lloyd‐Jones, D. M. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.146506 · Cited by 55
“Creatinine, mg/L 11 (4) 10 (3) 13 (5) 11 (4)”
de Camargo, A. A., Justino, T., de Andrade, C. H. S., Malaguti, C., & Corso, S. D. (2011) · Respiratory Care · doi:10.4187/respcare.01047 · Cited by 62
Prognostic assessment in COPD without lung function: the B-AE-D indices
Boeck, L., Soriano, J. B., Brusse-Keizer, M. G. J., Blasi, F., Κostikas, Κ., Boersma, W. G., Milenkovic, B. A., Louis, R. E., Lacoma, A., Djamin, R. S., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01485-2015 · Cited by 52
Self-citationRoss, J. C., Castaldi, P. J., Cho, M. H., Hersh, C. P., Rahaghi, F. N., Vegas‐Sánchez‐Ferrero, G., Parker, M. M., Litonjua, A. A., Sparrow, D., Dy, J., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1405oc · Cited by 53
Zatloukal, J., Brat, K., Neumannová, K., Voláková, E., Hejduk, K., Kočová, E., Kudela, O., Kopecký, M., Plutinský, M., & Koblížek, V. (2020) · Biomedical Papers · doi:10.5507/bp.2020.056 · Cited by 58
Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function
Allwood, B., Stolbrink, M., Baines, N., Louw, E. H., Wademan, D. T., Lupton-Smith, A. R., Nel, S., Maree, D., Mpagama, S. G., Osman, M., et al. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.20.0906 · Cited by 51
Shetty, B. S. P., Chaya, S. K., Kumar, S., Maheswarappa, M., Siddaiah, J. B., Lokesh, K. S., Ganguly, K., & Mahesh, P. A. (2021) · Toxics · doi:10.3390/toxics9040072 · Cited by 54
“Multidimensional body mass index (BMI (B), airflow obstruction (O), dyspnea (D), and exercise tolerance (E) (BODE) index was calculated [22].”
Method
Metadata
- Authors
- Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J.
- Affiliations
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Hospital Clínico Universitario de Caracas (VE)
- Boston University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-03-04
- Volume
- 350
- Issue
- 10
- Pages
- 1005-1012
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139347600
- Semantic Scholar
- 12606ed46f2e1cd6f56b679b445a8fda29690f65
- Cited by
- 4,015
- References
- 36
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 153 · 2023: 132 · 2022: 124 · 2021: 176 · 2020: 199 · 2019: 158 · 2018: 192 · 2017: 184 · 2016: 206 · 2015: 185 · 2014: 241 · 2013: 230 · 2012: 242
- FWCI
- 135.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Keywords
- chronic obstructive pulmonary disease, BODE index, body mass index, airflow obstruction, dyspnea, exercise capacity, 6-minute walk test, mortality prediction, FEV1, disease severity classification, respiratory mortality
- MeSH terms
- Aged, Airway Obstruction, Dyspnea, Forced Expiratory Volume, Humans, Middle Aged, Prospective Studies, Risk, Risk Factors, Severity of Illness Index, Body Mass Index, Exercise Tolerance, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.